Iprindole

Iprindole is an atypical tricyclic antidepressant (TCA) that was developed by Wyeth and introduced in 1967 for the treatment of major depressive disorder, primarily in the United Kingdom and Ireland. It is structurally a member of the indoles class and acts mainly as a non-selective monoamine reuptake inhibitor, inhibiting the reuptake of norepinephrine and, to a lesser extent, serotonin. Unlike typical TCAs, it has only weak antimuscarinic and sedative effects but retains significant antihistamine activity. Iprindole's mechanism may also involve down-regulation of beta adrenergic receptors and 5-HT2 (serotonin) receptors with chronic use. The drug is no longer marketed[1][2][8].

Brand names

ProndolGalaturTertran

Other names

iprindole